Optheapology

In a prior post I lightly dissed Circadian’s new name (ASX : CIR) – Opthea. In my defence, you surely knew it was coming… though I should clarify, for the avoidance of doubt, that I have always liked the name Opthea better than “sister company” Vegenics. Yuk. The word “vegenics” can only ever be credibly used in the following sentence…

A Little Rest

Hi there… it’s been a while. I hope you are doing fine? You’re looking great, by the way… I took a break. Between a pile of business travel over the past few weeks*, several new ventures getting off the ground and the pending arrival of my second child, I have just been swamped. But I…

The Questionable Ethics of Anisina – Part II

I have lost a lot of sleep this week about my prior post on the relationship between Novogen/Anisina (ASX : NRT) and the Kids’ Cancer Project. I received some fairly scathing emails from donors who are obviously very passionate about what the Kids’ Cancer Project represents and – if I am honest with you –…

The Questionable Ethics of Anisina

I really appreciate the value that many of the Long Tail readers bring to this site, and I’d particularly like to thank a couple of followers that sent me (both publicly and privately) the link to the Kids’ Cancer Project website that talks about Anisina (I have also take a PDF of it in case the page(s) gets…

A Tale of Two Companies

I honestly can’t recall the moment I felt compelled to bastardise Dickens. I suspect that it has been a gradual accumulation of neural triggers, little seismic bursts of thought association that gradually – over thousands of words – build into a tsunami of recognition that eventually crushes the civilisation of the mind. Thought association. Hmmmm. Was it the…

Novogen’s Graham Kelly : Jumped or Pushed?

Intriguing stuff – you no doubt know that today Dr. Graham Kelly, CEO of Novogen, resigned from the company. In a reasonably perfunctory statement, it has been announced that Dr. Kelly will “leave the Company to resume his work in non-oncology based early stage research.” Well, clearly, it would have to be non-oncology based research, because…